Movers roundup: Human Genome Sciences, Forest Labs
By
Associated Press
September 3, 2008
|
Among the stock activity stories for Wednesday, Sept. 3, from AP Financial News:
ROCKVILLE, Md. (AP) _ Shares of the Human Genome Sciences Inc. sank Wednesday after the biotech company reported what was seen as a disappointing result from the midstage trial of a cancer treatment.
NEW YORK (AP) _ Shares of Forest Laboratories Inc. fell to a seven-year low Wednesday following disappointing results from two late-stage trials of Forest's drug candidate aclidinium bromide.
NEW YORK (AP) _ Shares of Neurocrine Biosciences Inc. rose Wednesday after the company said its drug candidate elagolix met all its goals in a midstage safety trial, causing little bone density loss and reducing pain from endometriosis.
NEW YORK (AP) _ Shares of Green Mountain Coffee Roasters Inc. fell Wednesday after a Stifel Nicolaus analyst downgraded the stock, saying costs are likely to rise and growth in single-cup brewers may not meet expectations.